The FDA previously approved FoundationOne CDx, which uses a tumor tissue sample, and FoundationOne Liquid CDx, which uses a ...
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer—such as ...
If you have advanced prostate cancer, your health care provider may have told you about a medicine called Truqap (capivasertib). In June 2026, the FDA approved Truqap for certain adults with prostate ...
Prostate cancer treatment has undergone a remarkable transformation over the past decade, with the integration of androgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results